FDA APPROVED FOR COLORECTAL CANCER (CRC) SCREENING

Simplify screening

Ordering the Shield™ blood test is simple—take a blood sample and ship it out to Guardant Health's labs for analysis

Start screening

You can improve screening adherence
with the Shield blood test

Just a simple blood draw at any patient visit

+
  • Collect your patient’s blood sample
=
  • Ship to Guardant Health via FedEx Express® using the prepaid envelope in the kit

You’ll receive
actionable results
in ~2 weeks

These results will appear as “Negative” or “Positive”. When creating the order, you have the option to request that you are notified 24 hours before your patient, in the event of a "Positive" signal

Watch our
instructional videos

“Ordering takes a couple of clicks and it’s not time consuming or difficult at all for the staff to do”

—
Yulia Koltzova-Rang, MD
Internal Medicine

No in-house phlebotomy?
No problem

Our Patient Navigation Team is here to work with you to help your patients find a convenient phlebotomy option

1000s

of contracted lab partners

Patient service centers

Mobile phlebotomy units

In-office blood draws with a Shield-contracted phlebotomist

Ready to take CRC screening adherence to the next level?

Sign up to start screening with Shield

Request info

Important Product Information

Intended Use

The Shield™ test is a qualitative, in vitro diagnostic test intended to detect colorectal cancer derived alterations in cell-free DNA from blood collected in the Guardant Shield Blood Collection Kit.
Shield is indicated for colorectal cancer screening in individuals at average risk for the disease, age 45 years or older. Patients with a positive result should be followed by colonoscopy. Shield is not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk individuals. This test is performed at Guardant Health, Inc.

Precaution: Based on data from clinical studies, Shield has limited detection (55%-65%) of Stage I colorectal cancer and does not detect 87% of precancerous lesions. One out of 10 patients with a negative Shield result may have a precancer that would have been detected by a screening colonoscopy. Shield demonstrated high detection of Stage II, III, and IV colorectal cancer.

Limitations and Other Important Information: The Shield test is not indicated for patients that have personal history of colorectal cancer, adenomas, or other related cancers; or those who had a positive result on another colorectal cancer screening method within the last six months, have been diagnosed with a condition associated with high risk for colorectal cancer such as Inflammatory Bowel Disease (IBD), chronic ulcerative colitis (CUC), Crohn’s disease; or who have a family history of colorectal cancer, or certain hereditary syndromes. Providers should discuss the most appropriate screening test to use with patients depending on their medical history and individual circumstances. Shield may produce a false negative or false positive result. A false negative result may occur when the Shield test does not detect a colorectal tumor signal while a colonoscopy identifies a colorectal cancer. A negative result does not guarantee the absence of colorectal cancer or advanced adenoma, and patients should continue participating in colorectal cancer screening programs at the appropriate guideline-recommended intervals. A false positive result may occur when the Shield test generates a positive result while a colonoscopy will not find colorectal cancer or advanced adenoma.

Please read our Provider Brochure for complete product information about the Shield test including full safety information.